Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00927537
First received: June 24, 2009
Last updated: September 1, 2013
Last verified: September 2013

June 24, 2009
September 1, 2013
April 2008
October 2011   (final data collection date for primary outcome measure)
Blood pressure [ Time Frame: After 1-2 weeks, 1month, 3-4 months ] [ Designated as safety issue: No ]
Blood pressure [ Time Frame: After 1-2 weeks,1 month,3-4 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00927537 on ClinicalTrials.gov Archive Site
  • Change in Mean heart rate (bpm) [ Time Frame: Baseline and 3-4 month ] [ Designated as safety issue: No ]
  • Change in Mean Weight (kg) [ Time Frame: Baseline and 3-4 month ] [ Designated as safety issue: No ]
  • Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose) [ Time Frame: Baseline and 3-4 month ] [ Designated as safety issue: No ]
  • Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician. [ Time Frame: After 3-4 month ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Community

Hypertension
  • Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
    Patients under daily life treatment receiving Kinzal according to local drug information.
  • Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
    Patients under daily life treatment receiving Kinzalplus according to local drug information.
  • Group 1
    Intervention: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
  • Group 2
    Intervention: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2052
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion Criteria:

  • According to the local drug information
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00927537
13599, KL0810CH
No
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP